Search Results - "Toomey, John R."

Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype by Ivashchenko, Christine Y, Pipes, Gordon C, Lozinskaya, Irina M, Lin, Zuojun, Xiaoping, Xu, Needle, Saul, Grygielko, Eugene T, Hu, Erding, Toomey, John R, Lepore, John J, Willette, Robert N

“…Human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) have been recently derived and are used for basic research, cardiotoxicity assessment,…”
Get more information

Factor Xa Inhibitors:  S1 Binding Interactions of a Series of N-{(3S)-1-[(1S)-1-Methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides by Chan, Chuen, Borthwick, Alan D, Brown, David, Burns-Kurtis, Cynthia L, Campbell, Matthew, Chaudry, Laiq, Chung, Chun-wa, Convery, Máire A, Hamblin, J. Nicole, Johnstone, Lisa, Kelly, Henry A, Kleanthous, Savvas, Patikis, Angela, Patel, Champa, Pateman, Anthony J, Senger, Stefan, Shah, Gita P, Toomey, John R, Watson, Nigel S, Weston, Helen E, Whitworth, Caroline, Young, Robert J, Zhou, Ping

“…Factor Xa inhibitory activities for a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides with different P1…”
Get full text

Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function by Erhardt, Joseph A, Erickson-Miller, Connie L, Aivado, Manuel, Abboud, Melanie, Pillarisetti, Kodandaram, Toomey, John R

“…Objective The thrombopoietin receptor (TPOR) is a therapeutic target for treatment of thrombocytopenia because stimulation of this receptor results in enhanced…”
Get full text

Antithrombotic Efficacy of a Novel Murine Antihuman Factor IX Antibody in Rats by Feuerstein, Giora Z, Patel, Arun, Toomey, John R, Bugelski, Peter, Nichols, Andrew J, Church, William R, Valocik, Richard, Koster, Paul, Baker, Audrey, Blackburn, Michael N

“…A murine antihuman factor IX monoclonal antibody (BC2) has been generated and evaluated for its capacity to prolong the activated partial thromboplastin time…”
Get full text

Effect of Tissue Factor Deficiency on Mouse and Tumor Development by Toomey, John R., Kratzer, Kenneth E., Lasky, Nina M., Broze, George J.

“…Previous reports suggest that tissue factor (TF) may play an essential role in embryonic vascular development and tumor angiogenesis. To further examine this…”
Get full text

High FGF23 Levels Failed to Predict Cardiac Hypertrophy in Animal Models of Hyperphosphatemia and Chronic Renal Failure by Moench, Ian, Aravindhan, Karpagam, Kuziw, Joanne, Schnackenberg, Christine G, Willette, Robert N, Toomey, John R, Gatto, Gregory J

“…Abstract Increased fibroblast growth factor 23 (FGF23) levels are an independent predictor for adverse cardiac events suggesting a role as a link that drives…”
Get full text

The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa by Aktimur, Aysar, Gabriel, Melanie A, Gailani, David, Toomey, John R

“…During hemostasis, factor IX is activated to factor IXabeta by factor VIIa and factor XIa. The glutamic acid-rich gamma-carboxyglutamic acid (Gla) domain of…”
Get full text

Reconsidering phenotypic heart failure drug discovery by Toomey, John R, Upson, John J

“…With a few notable exceptions, heart failure (HF) drug development has faced substantial attrition while translating preclinical discoveries into clinical…”
Get full text

The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs by Watson, Nigel S., Adams, Carl, Belton, David, Brown, David, Burns-Kurtis, Cynthia L., Chaudry, Laiq, Chan, Chuen, Convery, Máire A., Davies, David E., Exall, Anne M., Harling, John D., Irvine, Stephanie, Irving, Wendy R., Kleanthous, Savvas, McLay, Iain M., Pateman, Anthony J., Patikis, Angela N., Roethke, Theresa J., Senger, Stefan, Stelman, Gary J., Toomey, John R., West, Robert I., Whittaker, Caroline, Zhou, Ping, Young, Robert J.

“…The discovery of potent and long-acting series of orally available factor Xa inhibitors with tetrahydroisoquinoline and benzazepine motifs is described. The…”
Get full text

Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs by Young, Robert J., Adams, Carl, Blows, Mike, Brown, David, Burns-Kurtis, Cynthia L., Chan, Chuen, Chaudry, Laiq, Convery, Máire A., Davies, David E., Exall, Anne M., Foster, Graham, Harling, John D., Hortense, Eric, Irvine, Stephanie, Irving, Wendy R., Jackson, Steve, Kleanthous, Savvas, Pateman, Anthony J., Patikis, Angela N., Roethka, Theresa J., Senger, Stefan, Stelman, Gary J., Toomey, John R., West, Robert I., Whittaker, Caroline, Zhou, Ping, Watson, Nigel S.

“…The discovery of potent series of orally available factor Xa inhibitors with aminoindane and phenylpyrrolidine motifs is described. The rational design,…”
Get full text

Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with biaryl P4 motifs by Young, Robert J., Borthwick, Alan D., Brown, David, Burns-Kurtis, Cynthia L., Campbell, Matthew, Chan, Chuen, Charbaut, Marie, Chung, Chun-wa, Convery, Máire A., Kelly, Henry A., Paul King, N., Kleanthous, Savvas, Mason, Andrew M., Pateman, Anthony J., Patikis, Angela N., Pinto, Ivan L., Pollard, Derek R., Senger, Stefan, Shah, Gita P., Toomey, John R., Watson, Nigel S., Weston, Helen E.

“…Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating biaryl…”
Get full text

Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs by Kleanthous, Savvas, Borthwick, Alan D., Brown, David, Burns-Kurtis, Cynthia L., Campbell, Matthew, Chaudry, Laiq, Chan, Chuen, Clarte, Marie-Olive, Convery, Máire A., Harling, John D., Hortense, Eric, Irving, Wendy R., Irvine, Stephanie, Pateman, Anthony J., Patikis, Angela N., Pinto, Ivan L., Pollard, Derek R., Roethka, Theresa J., Senger, Stefan, Shah, Gita P., Stelman, Gary J., Toomey, John R., Watson, Nigel S., West, Robert I., Whittaker, Caroline, Zhou, Ping, Young, Robert J.

“…The discovery of a potent series of orally available Factor Xa inhibitors with monoaryl P4 motifs is described. Structure and property based drug design was…”
Get full text

Structure and property based design of factor Xa inhibitors: Biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs by Young, Robert J., Borthwick, Alan D., Brown, David, Burns-Kurtis, Cynthia L., Campbell, Matthew, Chan, Chuen, Charbaut, Marie, Convery, Máire A., Diallo, Hawa, Hortense, Eric, Irving, Wendy R., Kelly, Henry A., King, N. Paul, Kleanthous, Savvas, Mason, Andrew M., Pateman, Anthony J., Patikis, Angela N., Pinto, Ivan L., Pollard, Derek R., Senger, Stefan, Shah, Gita P., Toomey, John R., Watson, Nigel S., Weston, Helen E., Zhou, Ping

“…Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating basic…”
Get full text

Selective and dual action orally active inhibitors of thrombin and factor Xa by Young, Robert J., Brown, David, Burns-Kurtis, Cynthia L., Chan, Chuen, Convery, Máire A., Hubbard, Julia A., Kelly, Henry A., Pateman, Anthony J., Patikis, Angela, Senger, Stefan, Shah, Gita P., Toomey, John R., Watson, Nigel S., Zhou, Ping

“…The synthetic entry to new classes of dual fXa/thrombin and selective thrombin inhibitors with significant oral bioavailability is described. The observed…”
Get full text

Antithrombotic Potential of GW813893: A Novel, Orally Active, Active-site Directed Factor Xa Inhibitor by Abboud, Melanie A, Needle, Saul J, Burns-Kurtis, Cynthia L, Valocik, Richard E, Koster, Paul F, Amour, Augustin J, Chan, Chuen, Brown, David, Chaudry, Laiq, Zhou, Ping, Patikis, Angela, Patel, Champa, Pateman, Anthony J, Young, Rob J, Watson, Nigel S, Toomey, John R

“…BACKGROUND:Factor Xa (FXa) has been a target of considerable interest for drug development efforts aimed at suppressing thrombosis. In this report, a new…”
Get full text

Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke by TOOMEY, John R, VALOCIK, Richard E, KOSTER, Paul F, GABRIEL, Melanie A, MCVEY, Matt, HART, Timothy K, OHLSTEIN, Eliot H, PARSONS, Andrew A, BARONE, Frank C

“…Although used clinically to prevent stroke, there are few examples of anticoagulant investigations in the treatment of acute thromboembolic stroke in animal…”
Get full text

An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis by Feuerstein, G Z, Toomey, J R, Valocik, R, Koster, P, Patel, A, Blackburn, M N

“…An inhibitory anti-factor IX/IXa antibody (BC2) has been investigated as an anti-thrombotic agent in a rat venous thrombosis model. The treatment of rats…”
Get more information

Comparing the Antithrombotic Efficacy of a Humanized Anti-factor IX(a) Monoclonal Antibody (SB 249417) to the Low Molecular Weight Heparin Enoxaparin In a Rat Model of Arterial Thrombosis by Toomey, John R, Blackburn, Michael N, Storer, Barbara L, Valocik, Richard E, Koster, Paul F, Feuerstein, Giora Z

“…A humanized inhibitory anti-factor IX(a) antibody (SB 249417) has been compared to enoxaparin (Lovenox) in a rat model of arterial thrombosis. Pretreatment of…”
Get full text

An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure by Thorneloe, Kevin S, Cheung, Mui, Bao, Weike, Alsaid, Hasan, Lenhard, Stephen, Jian, Ming-Yuan, Costell, Melissa, Maniscalco-Hauk, Kristeen, Krawiec, John A, Olzinski, Alan, Gordon, Earl, Lozinskaya, Irina, Elefante, Lou, Qin, Pu, Matasic, Daniel S, James, Chris, Tunstead, James, Donovan, Brian, Kallal, Lorena, Waszkiewicz, Anna, Vaidya, Kalindi, Davenport, Elizabeth A, Larkin, Jonathan, Burgert, Mark, Casillas, Linda N, Marquis, Robert W, Ye, Guosen, Eidam, Hilary S, Goodman, Krista B, Toomey, John R, Roethke, Theresa J, Jucker, Beat M, Schnackenberg, Christine G, Townsley, Mary I, Lepore, John J, Willette, Robert N

“…Pulmonary edema resulting from high pulmonary venous pressure (PVP) is a major cause of morbidity and mortality in heart failure (HF) patients, but current…”
Get more information

Activation of Caspase-3/Caspase-3-Like Activity in Rat Cardiomyocytes by an RGD Peptide, but not the GPIIb/IIIa Antagonist Lotrafiban by Erhardt, Joseph A., Ohlstein, Eliot H., Toomey, John R., Gabriel, Melanie A., Willette, Robert N., Yue, Tian-Li, Barone, Frank C., Parsons, Andrew A.

Get full text